See the DrugPatentWatch profile for methotrexate

Methotrexate is a commonly prescribed drug for various conditions such as rheumatoid arthritis, psoriasis, and certain types of cancer [1]. However, its use in elderly patients, particularly those with kidney dysfunction, requires careful consideration.

The kidneys play a crucial role in eliminating methotrexate from the body. As a result, impaired kidney function can lead to increased levels of methotrexate in the blood, which may cause toxicity [2].

Elderly patients are at a higher risk of developing kidney problems due to the natural aging process and other health conditions [3]. Therefore, healthcare providers must closely monitor renal function in elderly patients taking methotrexate.

Methotrexate-induced nephrotoxicity can manifest as acute kidney injury, interstitial nephritis, or crystalline nephropathy [4]. These conditions can lead to further complications such as electrolyte imbalances, fluid accumulation, and decreased kidney function.

To minimize the risk of methotrexate-induced nephrotoxicity in elderly patients, healthcare providers may adjust the dosage, administer intravenous fluids, and monitor renal function closely [5]. In some cases, alternative treatments may be considered.

In summary, methotrexate can have harmful effects on elderly kidneys, and healthcare providers must exercise caution when prescribing this drug to elderly patients. Close monitoring of renal function and appropriate dosage adjustments can help mitigate the risks associated with methotrexate use in this population.

Sources:
[1] <https://www.drugs.com/methotrexate.html>
[2] <https://www.ncbi.nlm.nih.gov/books/NBK557855/>
[3] <https://www.ncbi.nlm.nih.gov/books/NBK221732/>
[4] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145653/>
[5] <https://www.drugpatentwatch.com/drugs/methotrexate>